What is the recommended treatment for plantar psoriasis?

Treatment of Plantar Psoriasis

Start with combination topical therapy using calcipotriene plus betamethasone dipropionate as first-line treatment, and escalate to systemic biologics (particularly secukinumab, ixekizumab, or guselkumab) if topical therapy fails after 8-12 weeks.

First-Line Topical Therapy

The 2021 AAD-NPF guidelines provide clear direction for plantar psoriasis management 1:

• Combination calcipotriene/betamethasone dipropionate is the preferred initial approach (Strength A recommendation)

  • Can be used safely for up to 52 weeks without serious adverse events including HPA axis suppression
  • In general psoriasis studies, 69-74% of patients achieved clear/almost clear status with this combination
  • Apply once or twice daily

• Topical maxacalcitol (not available in US) can be considered specifically for palmoplantar psoriasis as initial treatment 1

• High-potency topical corticosteroids combined with vitamin D analogues using alternating schedules:

  • Vitamin D analogues twice daily on weekdays + high-potency corticosteroids twice daily on weekends (Strength B) 1
  • Morning high-potency corticosteroids + evening vitamin D analogues (Strength B) 1

Critical Pitfall to Avoid

Never combine salicylic acid with calcipotriene - the acidic pH inactivates calcipotriene and reduces effectiveness 1

Adjunctive Topical Measures

• Add emollients to corticosteroid therapy for 4-8 weeks to reduce itching, desquamation, and prevent quick relapse when corticosteroids are discontinued (Strength B) 1
• One RCT showed mometasone plus emollient improved palmoplantar skin area, desquamation, and symptoms compared to mometasone alone after 4 weeks 1

When to Escalate to Systemic Therapy

Plantar psoriasis is particularly treatment-resistant and significantly impacts quality of life despite limited body surface area involvement 2, 3. Escalate to systemic therapy when:

• Topical therapy fails after 8-12 weeks
• Functional impairment is severe (fissures, pain affecting ambulation)
• Patient cannot maintain topical regimen adherence

Men with palmoplantar involvement have the highest risk of treatment failure (HR 2.19, P < 0.001) and should be considered for earlier escalation 4

Systemic Biologic Therapy

Based on 2023 network meta-analysis of 15 RCTs examining biologics for palmoplantar psoriasis 5:

Ranked by efficacy for plantar psoriasis:

1. Secukinumab - highest probability of inducing complete resolution
2. Ixekizumab - ranked best for PPASI50 and PPASI75 improvement
3. Guselkumab - effective for both PP and palmoplantar pustulosis
4. Infliximab - ranked best for PPASI50/75 but less practical for chronic use

All examined biologics except infliximab significantly outperformed placebo 5

Alternative Systemic Options

• Apremilast (PDE4 inhibitor): Real-world data shows 83.33% achieved clear/almost clear palmoplantar psoriasis (PPPGA 0/1) at week 16 with good safety profile 6
  • Consider for patients who prefer oral therapy or have contraindications to biologics

Phototherapy Considerations

Phototherapy has limited utility for plantar psoriasis - patients with palmar/plantar involvement have significantly increased risk of treatment discontinuation (HR 1.48, P = 0.006), especially men (HR 2.19, P < 0.001) 4. Median treatment survival is only 30 months, similar to TNF inhibitors but inferior to newer biologics.

Treatment Algorithm Summary

1. Weeks 0-12: Calcipotriene/betamethasone dipropionate combination + emollients
2. Week 12 assessment: If inadequate response (especially in men or severe functional impairment), escalate to biologics
3. Biologic selection: Secukinumab or ixekizumab as first choice; guselkumab for pustular variant
4. Alternative: Apremilast for patients preferring oral therapy

The traditional stepwise approach of exhausting all topical options before systemic therapy is outdated for plantar psoriasis given its significant functional impact and high treatment resistance 2, 3.